Supplemental Material

Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines

Benjamin Ascher, MD, Berthold Rzany, MD, Sc.M, Philippe Kestemont, MD, Said Hilton, MD, Marc Heckmann, MD, Isaac Bodokh, MD, Ernst Magnus Noah, MD, PhD, Dominique Boineau, MD, Martina Kerscher, MD, Magali Volteau, PhD, Philippe Le Berre, MD, Philippe Picaut, PharmD

Aesthetic Surgery Journal 2019, DOI: 10.1093/asj/sjz003

Supplemental Table 1. Duration of treatment response based on (A) ILA and (B) SSA at maximum frown

Interval, days postinjection	ASI 50 U (N=125)		
	Subjects at start of interval, n	Non-responders during interval, n	Cumulative % (95% CI) of responders
A. Duration of treatment response, ILA of GL at maximum frown			
0-30	113	0	100 [100; 100]
30-60	112	14	88 [80; 92]
60-90	98	19	71 [61; 78]
90-120	78	20	52 [43; 61]
120-150	58	26	29 [43; 61]
150-180	31	18	5 [1; 13]
B. Duration of treatment response, SSA of GL at maximum frown			
0-30	100	4	96 [90; 98]
30-60	95	11	85 [76; 91]
60-90	84	18	67 [56; 75]
90-120	66	18	48 [38; 58]
120-150	47	10	38 [28; 47]
150-180	36	12	15 [5; 31]
180-210	-	-	-

Non-responders were defined as subjects who re-exhibited a severity grade of 2 or 3 during the interval. Cumulative percentage are Kaplan-Meier estimates. Discrepancies between the number of subjects at the start of each interval and the number of non-responders during the previous interval are due to subject who withdrew during an interval, without re-exhibiting a severity grade of 2 or 3.

ASI, abobotulinumtoxinA solution for injection; CI, confidence interval; GL, glabellar lines; ILA, investigator' live assessment; SSA, subject's self-assessment.